Skip Navigation

European Heart Journal 1985 6(6):518-524;
Copyright © 1985 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by GOY, J.-J.
Right arrow Articles by SIGWART, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GOY, J.-J.
Right arrow Articles by SIGWART, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1985 The European Society of Cardiology

Conversion of supraventricular arrhythmias to sinus rhythm using flecainide

J.-J. GOY, M. GRBIC, M. HURNI, L. FINCI, R. MAENDLY, J. DUC and U. SIGWART

Department of Cardiology, University Hospital 1011 Lausanne, Switzerland

Received 2 November 1984; revised 28 March 1985; .

Docteur J.-J. Goy, Division de cardiologie, CHUV, Rue du Bugnon, 1011 Lausanne, Switzerland.

Abstract

We evaluated the efficacy of flecainide acetate (given intravenously to a maximal dose of2 mg kg–1 and then orally in a dose of 100 mg b.d. or 100 mg t.d.s.) in the conversion to sinus rhythm of 50 patients exhibiting supraventricular arrhythmias (39 with atrial fibrillation, 6 with atrial flutter, 4 with supraventricu tachycardia and onewith supraventricular tachycardia in association with the Wolff—Parkinson—White syndrome). Conversion was achieved in 36 patients (72%) (29 cases with atrial fibrillation, 4 cases with supraventricular tachycardia, 2 cases with atrial flutter and one case with Wolff—Parkinson–White syndrome), over a mean period of 7.4 ± 9 h. The patients in which conversion was achieved had arrhythmias which had been in existence for a shorter time (5.3 ± 9.8 days) than those in which conversion was not achieved (16.7 ± 26.2 days) (P<0.01). The mean dosage of flecainide used to achieve conversion was 2.5 ± 2.36 mg kg–1. Flecainide appears to be an effective agent for the conversion to sinus rhythm of atrial fibrillation and supraventricular tachycardias. Its efficacy in cases of atrial flutter has not yet been demonstrated.

Key Words: Antiarrhythmic drug • atrial fibrillation • atrial flutter


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.